WOONSOCKET, R.I., April 3, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Thursday, May 1st, 2025, at 8:00 a.m. ET to discuss first quarter 2025 financial results.
An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.
About CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2024, the Company had more than 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics, a leading pharmacy benefits manager with approximately 90 million plan members, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 36 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Media contact
Ethan Slavin
860-273-6095
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor contact
Larry McGrath
800-201-0938
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$71.43 |
| Daily Change: | 0.61 0.86 |
| Daily Volume: | 5,467,274 |
| Market Cap: | US$90.720B |
July 10, 2025 February 17, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
